{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:53:35Z","timestamp":1793436815887,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.03.017","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:36:32Z","timestamp":1782992192000},"page":"669-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Surveillance of patients at risk of liver cancer: Expert opinions"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-2464","authenticated-orcid":false,"given":"Terry Cheuk-Fung","family":"Yip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0565-1083","authenticated-orcid":false,"given":"Hamish","family":"Innes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-9389","authenticated-orcid":false,"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-1430","authenticated-orcid":false,"given":"Peter","family":"Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.03.017_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","article-title":"Liver cancer in 2021: global burden of disease study","volume":"82","author":"Tan","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jhep.2024.06.004","article-title":"Rare primary liver cancers: an EASL position paper","volume":"81","author":"Wege","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/hep.27598","article-title":"The clinical course of cirrhosis: the importance of multistate models and competing risks analysis","volume":"62","author":"Jepsen","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib6","article-title":"Cholangiocarcinoma in Denmark: time-trends in incidence and mortality","volume":"7","author":"Jensen","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.03.017_bib7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.14309\/ajg.0000000000003077","article-title":"Primary liver cancer risk and mortality in patients with alcohol-related cirrhosis in England and Denmark: observational cohort studies","volume":"120","author":"Jensen","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.03.017_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2023.11.021","article-title":"Preventing liver disease with policy measures to tackle alcohol consumption and obesity: the HEPAHEALTH II study","volume":"80","author":"Retat","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.03.017_bib10","author":"Wilson"},{"key":"10.1016\/j.jhep.2026.03.017_bib11","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180200","article-title":"Screening and surveillance-principles and practice","volume":"91","author":"Steele","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jhep.2026.03.017_bib12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jhep.2024.04.035","article-title":"Improving HCC surveillance with abbreviated MRI: a call to integrate and innovate?","volume":"81","author":"Ronot","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cgh.2021.02.024","article-title":"Patient preferences for hepatocellular carcinoma surveillance parameters","volume":"20","author":"Woolen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib14","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.03.017_bib15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/apt.16779","article-title":"Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study","volume":"55","author":"Chong","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.03.017_bib16","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.22441","article-title":"Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis","volume":"48","author":"Charatcharoenwitthaya","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib17","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.24570","article-title":"Cancer surveillance in patients with primary sclerosing cholangitis","volume":"54","author":"Razumilava","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2021.01.041","article-title":"Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis","volume":"75","author":"Gupta","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jhep.2019.12.001","article-title":"Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound","volume":"72","author":"Park","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib20","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaoncol.2016.3147","article-title":"MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma","volume":"3","author":"Kim","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.03.017_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2024.03.048","article-title":"Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC","volume":"81","author":"Kim","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1053\/j.gastro.2024.12.035","article-title":"Noncontrast magnetic resonance imaging vs ultrasonography for hepatocellular carcinoma surveillance: a randomized, single-center trial","volume":"168","author":"Rhee","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.03.017_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jhep.2024.03.030","article-title":"Developing and validating clinical prediction models in hepatology - an overview for clinicians","volume":"81","author":"Strandberg","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2019.12.005","article-title":"Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"72","author":"Yip","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib26","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2026.03.017_bib27","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.03.017_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib29","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib30","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jhep.2018.07.018","article-title":"Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy","volume":"69","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib31","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib32","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1016\/j.cgh.2023.02.004","article-title":"Diabetes mellitus impacts on the performance of hepatocellular carcinoma risk scores in chronic hepatitis B patients","volume":"21","author":"Yip","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jhep.2018.02.032","article-title":"Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B","volume":"69","author":"Hsu","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/infdis\/jiz477","article-title":"Real-world effectiveness from the asia pacific rim liver consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy","volume":"221","author":"Yang","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2026.03.017_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2023.09.011","article-title":"PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B","volume":"80","author":"Chun","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib36","article-title":"Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis","volume":"4","author":"Wong","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.03.017_bib37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jhep.2021.09.025","article-title":"An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B","volume":"76","author":"Kim","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib38","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/liv.15597","article-title":"A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B","volume":"43","author":"Lee","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.03.017_bib39","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jhep.2024.12.029","article-title":"AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B","volume":"82","author":"Shin","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib40","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2020.01.007","article-title":"Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B","volume":"72","author":"Papatheodoridis","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib41","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 Years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.03.017_bib42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib43","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","article-title":"HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease","volume":"76","author":"Semmler","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib44","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jhep.2020.05.052","article-title":"Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status","volume":"73","author":"Audureau","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib45","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2023.05.042","article-title":"Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals","volume":"79","author":"Minami","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib46","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2022.11.003","article-title":"Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis","volume":"78","author":"Nahon","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib47","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2024.10.035","article-title":"Phase 3 validation of PAaM for hepatocellular carcinoma risk stratification in cirrhosis","volume":"168","author":"Fujiwara","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.03.017_bib48","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.07.033","article-title":"Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis","volume":"68","author":"Sharma","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib49","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib50","article-title":"Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection","volume":"3","author":"Innes","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.03.017_bib51","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/j.jhep.2025.07.024","article-title":"Male-to-female ratios in the risk of hepatocellular carcinoma: a nationwide study of Danish patients with viral or non-viral cirrhosis","volume":"83","author":"Bjorn","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-085541","article-title":"Prospective cohort for early detection of liver cancer (Pearl): a study protocol","volume":"14","author":"Khanna","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhep.2026.03.017_bib53","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1053\/j.gastro.2023.06.027","article-title":"Incidence and risk factors for hepatocellular carcinoma in cirrhosis: the multicenter hepatocellular carcinoma early detection strategy (HEDS) study","volume":"165","author":"Reddy","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.03.017_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41416-023-02308-9","article-title":"Deceptive measures of progress in the NHS long-term plan for cancer: case-based vs. population-based measures","volume":"129","author":"Oke","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2026.03.017_bib55","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamainternmed.2023.4064","article-title":"The future of cancer screening-guided without conflicts of interest","volume":"183","author":"Adami","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2026.03.017_bib56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jhep.2026.03.017_bib57","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis","volume":"77","author":"Singal","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib58","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib59","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/aje\/kwn120","article-title":"Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival","volume":"168","author":"Duffy","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhep.2026.03.017_bib60","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1053\/j.gastro.2018.06.079","article-title":"No association between screening for hepatocellular carcinoma and reduced cancer-related mortality in patients with cirrhosis","volume":"155","author":"Moon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.03.017_bib61","first-page":"1","article-title":"HCC-surveillance is associated with improved HCC-related mortality in patients with cirrhosis - a case-control study","author":"Hegmar","year":"2025","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.03.017_bib62","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jhep.2020.11.023","article-title":"Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B","volume":"74","author":"Su","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib63","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/oxfordjournals.aje.a116368","article-title":"Approaches to the analysis of case-control studies of the efficacy of screening for cancer","volume":"135","author":"Weiss","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhep.2026.03.017_bib64","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/s43018-023-00618-8","article-title":"Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study","volume":"4","author":"Zeng","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jhep.2026.03.017_bib65","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000121","article-title":"The role of natural experiments in hepatology research: filling the gap between clinical trials and service evaluations","volume":"7","author":"Buchanan","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2026.03.017_bib66","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40471-023-00327-x","article-title":"A tutorial on applying the difference-in-differences method to health data","volume":"11","author":"Rothbard","year":"2024","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.jhep.2026.03.017_bib67","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.510270140","article-title":"Screening for hepatocellular carcinoma","volume":"27","author":"Collier","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib68","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference. European association for the study of the liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib69","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12072-010-9165-7","article-title":"Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma","volume":"4","author":"Omata","year":"2010","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2026.03.017_bib70","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2026.03.017_bib72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/CLEP.S393118","article-title":"Effects of curative-intent treatments on hepatocellular carcinoma survival in alcohol-related cirrhosis: a nationwide study","volume":"15","author":"Kraglund","year":"2023","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jhep.2026.03.017_bib73","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2019.11.016","article-title":"The chances of hepatic resection curing hepatocellular carcinoma","volume":"72","author":"Cucchetti","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib74","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/s41416-023-02188-z","article-title":"'Potentially curative therapies' for hepatocellular carcinoma: how many patients can actually be cured?","volume":"128","author":"Cucchetti","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2026.03.017_bib75","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/HEP.0000000000000528","article-title":"Hepatocellular carcinoma surveillance may be associated with potential psychological harms in patients with cirrhosis","volume":"79","author":"Narasimman","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib76","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/hep.28895","article-title":"An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"65","author":"Atiq","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib77","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jnci\/djae228","article-title":"Benefits and harms of hepatocellular carcinoma screening outreach in patients with cirrhosis: a multicenter randomized clinical trial","volume":"117","author":"Singal","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2026.03.017_bib78","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1055\/s-0037-1608775","article-title":"Overdiagnosis: an understudied issue in hepatocellular carcinoma surveillance","volume":"37","author":"Rich","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2026.03.017_bib79","article-title":"Nonalcoholic fatty liver disease-related hepatocellular carcinoma growth rates and their clinical outcomes","volume":"7","author":"Benhammou","year":"2021","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.jhep.2026.03.017_bib80","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/hepr.12672","article-title":"Length time bias in surveillance for hepatocellular carcinoma and how to avoid it","volume":"46","author":"Cucchetti","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2026.03.017_bib81","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/jamainternmed.2023.3781","article-title":"Testing whether cancer screening saves lives: implications for randomized clinical trials of multicancer screening","volume":"183","author":"Welch","year":"2023","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2026.03.017_bib82","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/liv.13151","article-title":"The clinical course of alcoholic cirrhosis: development of comorbid diseases. A Danish nationwide cohort study","volume":"36","author":"Jepsen","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.03.017_bib83","author":"Precey"},{"key":"10.1016\/j.jhep.2026.03.017_bib89","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/HEP.0000000000001203","article-title":"Value of HCC surveillance in a landscape of emerging surveillance options: perspectives of a multi-stakeholder modified Delphi panel","volume":"82","author":"Singal","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib92","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bpg.2014.08.008","article-title":"Surveillance for hepatocellular carcinoma","volume":"28","author":"Sherman","year":"2014","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2026.03.017_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2308","article-title":"Choosing Wisely in the UK: the Academy of Medical Royal Colleges' initiative to reduce the harms of too much medicine","volume":"350","author":"Malhotra","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2026.03.017_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.03.023","article-title":"The ethics of risk-stratified cancer screening","volume":"187","author":"Dennison","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2026.03.017_bib95","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib96","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jhep.2025.01.026","article-title":"Moving diagnosis of liver fibrosis into the community","volume":"83","author":"Pose","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib97","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000191","article-title":"Cost-effectiveness analysis of noninvasive tests to identify advanced fibrosis in non-alcoholic fatty liver disease","volume":"7","author":"Gruneau","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2026.03.017_bib98","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.14309\/ajg.0000000000003332","article-title":"Cost-utility analysis of noninvasive tests to initiate hepatocellular carcinoma surveillance in metabolic dysfunction-associated steatotic liver disease","volume":"120","author":"Decharatanachart","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.03.017_bib99","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: what, why, and how?","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2026.03.017_bib100","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jhep.2020.12.029","article-title":"We need stronger evidence for (or against) hepatocellular carcinoma surveillance","volume":"74","author":"Jepsen","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib101","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.70403","article-title":"Meta-analysis: utilisation of hepatocellular carcinoma surveillance","volume":"63","author":"Tang","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.03.017_bib102","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.31309","article-title":"Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis","volume":"73","author":"Wolf","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib103","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib104","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jhep.2023.12.031","article-title":"Inequities in primary liver cancer in Europe: the state of play","volume":"80","author":"Kondili","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jhep.2023.02.022","article-title":"International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance","volume":"79","author":"Singal","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/v17020265","article-title":"The key importance of screening underprivileged people in order to achieve global hepatitis virus elimination targets","volume":"17","author":"Gragnani","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2026.03.017_bib107","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jhep.2021.09.024","article-title":"Asian perspective on NAFLD-associated HCC","volume":"76","author":"Yip","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib108","article-title":"Use of liver stiffness measurement for HCC risk stratification in metabolic dysfunction-associated steatotic liver disease","author":"John","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib109","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1136\/gutjnl-2025-334981","article-title":"Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease","volume":"74","author":"Lai","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2026.03.017_bib110","doi-asserted-by":"crossref","first-page":"570","DOI":"10.14309\/ajg.0000000000002953","article-title":"The liver cirrhosis network cohort study: cirrhosis definition, study population, and endpoints","volume":"120","author":"Tapper","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.03.017_bib111","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/apt.12450","article-title":"Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States","volume":"38","author":"Tan","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.03.017_bib112","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/hep.32284","article-title":"Overdiagnosis of hepatocellular carcinoma: prevented by guidelines?","volume":"75","author":"Rich","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.017_bib113","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/MEG.0000000000001357","article-title":"Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir\/tenofovir","volume":"31","author":"Yu","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib114","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3350\/cmh.2016.0086","article-title":"Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B","volume":"23","author":"Sohn","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib115","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1136\/gutjnl-2015-310818","article-title":"Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B","volume":"65","author":"Poh","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2026.03.017_bib116","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jhep.2013.09.029","article-title":"Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B","volume":"60","author":"Wong","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib117","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2009.27.4456","article-title":"Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection","volume":"28","author":"Yang","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.03.017_bib118","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/liv.14666","article-title":"GES: a validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals","volume":"40","author":"Shiha","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.03.017_bib119","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/s41598-022-05196-w","article-title":"A scoring system for predicting hepatocellular carcinoma risk in alcoholic cirrhosis","volume":"12","author":"Lee","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2026.03.017_bib120","article-title":"Liver stiffness-based risk prediction model for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2026.03.017_bib121","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.017_bib122","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00535-016-1228-7","article-title":"Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases","volume":"52","author":"Aoki","year":"2017","journal-title":"J Gastroenterol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:53:54Z","timestamp":1789491234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":114,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0168827826001431"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.017","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surveillance of patients at risk of liver cancer: Expert opinions","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}